Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotech company Arius Research has been granted two US patents for antibodies; one patent within the CD63 program, which has been licensed to the company's partner Genentech, and a second patent within the carcinoembryonic antigen program.
Subscribe to our email newsletter
US patent 7,256,272 covers composition of matter claims for a CD63 targeting antibody and clone. Arius says that the CD63 targeting antibody has the potential to recruit the body’s own defense system to attack cancer and has been shown to prevent tumor growth and enhance survival in breast cancer models.
US Patent 7,256,271 contains claims on a targeting antibody and clone composition of matter. Carcinoembryonic antigen (CEA) is a broadly expressed tumor marker and Arius’s CEA targeting antibody has demonstrated potent anti-tumour activity in colon and breast cancer models, according to the company.